NeuroOne Regains Compliance With Nasdaq Minimum Bid Price Requirement

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it has received a notification letter from Nasdaq confirming it has regained compliance with the Minimum Bid Price Requirement under Nasdaq Marketplace Rule 5550(a)(2). The company had previously been notified of non-compliance on May 6, 2025, after its closing bid price remained below $1.00 per share for 30 consecutive business days. Nasdaq granted a 180-day extension on November 4, 2025, extending the compliance deadline to May 4, 2026.

To address the deficiency, NeuroOne effected a 1-for-6 reverse stock split that became effective at 5:00 p.m. Eastern Time on April 15, 2026. The company's common stock began trading on a split-adjusted basis at the market open on April 16, 2026, under the same symbol "NMTC" but with a new CUSIP number, 64130M308. The reverse split increased the per-share price, allowing the company to meet the $1.00 minimum bid requirement.

NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. Its FDA-cleared product portfolio includes the Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for brain procedures, and OneRF® Trigeminal Nerve Ablation System. The company also has research and development programs in drug delivery, basivertebral nerve ablation, and spinal cord stimulation. More information is available at nmtc1.com.

Regaining compliance with Nasdaq's listing requirements is a significant milestone for NeuroOne, as it removes the immediate risk of delisting and provides continued access to the public capital markets. This development ensures the company can maintain its listing on the Nasdaq Capital Market, which is crucial for investor confidence and liquidity. The reverse stock split, while adjusting the share count, does not alter the company's fundamental value but enables it to meet exchange standards. Investors should note that the new CUSIP number reflects the structural change. The closure of this matter allows NeuroOne to focus on its commercial and research activities without the overhang of a potential delisting.